154 related articles for article (PubMed ID: 20175919)
1. Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemia.
Rogers SL; Zhao Y; Jiang X; Eaves CJ; Mager DL; Rouhi A
Mol Cancer; 2010 Feb; 9():41. PubMed ID: 20175919
[TBL] [Abstract][Full Text] [Related]
2. CD34+CD7+ leukemic progenitor cells may be involved in maintenance and clonal evolution of chronic myeloid leukemia.
Kosugi N; Ebihara Y; Nakahata T; Saisho H; Asano S; Tojo A
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):505-11. PubMed ID: 15701834
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34
Maupetit-Mehouas S; Court F; Bourgne C; Guerci-Bresler A; Cony-Makhoul P; Johnson H; Etienne G; Rousselot P; Guyotat D; Janel A; Hermet E; Saugues S; Berger J; Arnaud P; Berger MG
Mol Oncol; 2018 Jun; 12(6):814-829. PubMed ID: 29575763
[TBL] [Abstract][Full Text] [Related]
4. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
[TBL] [Abstract][Full Text] [Related]
5. High expression of CD7 on CD34+ cells is not linked to deletion of derivative chromosome 9 or lack of dendritic cells in chronic myeloid leukaemia.
Fløisand Y; Normann AP; Heim S; Lund-Johansen F; Tjønnfjord GE
Scand J Clin Lab Invest; 2008; 68(2):93-8. PubMed ID: 17852828
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.
Yong AS; Szydlo RM; Goldman JM; Apperley JF; Melo JV
Blood; 2006 Jan; 107(1):205-12. PubMed ID: 16144796
[TBL] [Abstract][Full Text] [Related]
7. CD7 expression by CD34+ cells in CML patients, of prognostic significance?
Normann AP; Egeland T; Madshus IH; Heim S; Tjønnfjord GE
Eur J Haematol; 2003 Oct; 71(4):266-75. PubMed ID: 12950236
[TBL] [Abstract][Full Text] [Related]
8. CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation.
Röhrs S; Scherr M; Romani J; Zaborski M; Drexler HG; Quentmeier H
J Hematol Oncol; 2010 Apr; 3():15. PubMed ID: 20398252
[TBL] [Abstract][Full Text] [Related]
9. CD7 expression on CD34+ cells from chronic myeloid leukaemia in chronic phase.
Martín-Henao GA; Quiroga R; Sureda A; García J
Am J Hematol; 1999 Jul; 61(3):178-86. PubMed ID: 10398310
[TBL] [Abstract][Full Text] [Related]
10. High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.
Yong AS; Rezvani K; Savani BN; Eniafe R; Mielke S; Goldman JM; Barrett AJ
Blood; 2007 Jul; 110(2):770-5. PubMed ID: 17412886
[TBL] [Abstract][Full Text] [Related]
11. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profile of circulating CD34(+) cells and granulocytes in chronic myeloid leukemia.
Čokić VP; Mojsilović S; Jauković A; Kraguljac-Kurtović N; Mojsilović S; Šefer D; Mitrović Ajtić O; Milošević V; Bogdanović A; Đikić D; Milenković P; Puri RK
Blood Cells Mol Dis; 2015 Dec; 55(4):373-81. PubMed ID: 26460262
[TBL] [Abstract][Full Text] [Related]
13. Separase activity distribution can be a marker of major molecular response and proliferation of CD34
Spiess B; Kleiner H; Flach J; Fabarius A; Saussele S; Hofmann WK; Seifarth W
Ann Hematol; 2020 May; 99(5):991-1006. PubMed ID: 32253454
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
List AF; Spier CS; Grogan TM; Johnson C; Roe DJ; Greer JP; Wolff SN; Broxterman HJ; Scheffer GL; Scheper RJ; Dalton WS
Blood; 1996 Mar; 87(6):2464-9. PubMed ID: 8630412
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia.
Maguer-Satta V; Petzer AL; Eaves AC; Eaves CJ
Blood; 1996 Sep; 88(5):1796-804. PubMed ID: 8781437
[TBL] [Abstract][Full Text] [Related]
16. [The immunophenotypic analysis of CD7+ and (or) CD56+ acute myeloid leukemic stem cells and its applications in minimal residual disease detection].
Cao H; Wang YZ; Wu HH; Chang Y; Hao L; Chen SS; Huang XJ; Lu DP; Liu YR
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):23-8. PubMed ID: 18512311
[TBL] [Abstract][Full Text] [Related]
17. GPX3 promoter is methylated in chronic myeloid leukemia.
Yao DM; Zhou JD; Zhang YY; Yang L; Wen XM; Yang J; Guo H; Chen Q; Lin J; Qian J
Int J Clin Exp Pathol; 2015; 8(6):6450-7. PubMed ID: 26261521
[TBL] [Abstract][Full Text] [Related]
18. Methylation status of DDIT3 gene in chronic myeloid leukemia.
Wang YL; Qian J; Lin J; Yao DM; Qian Z; Zhu ZH; Li JY
J Exp Clin Cancer Res; 2010 May; 29(1):54. PubMed ID: 20492726
[TBL] [Abstract][Full Text] [Related]
19. Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia.
Zhang X; Yang L; Liu X; Nie Z; Wang X; Pan Y; Luo J
Br J Haematol; 2017 Sep; 178(5):728-738. PubMed ID: 28480959
[TBL] [Abstract][Full Text] [Related]
20. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
